Evolent Health (NYSE:EVH) Receives Market Outperform Rating from JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Evolent Health (NYSE:EVH) in a research report report published on Friday,Benzinga reports. JMP Securities currently has a $12.00 price objective on the technology company’s stock.

Several other research firms have also recently weighed in on EVH. Canaccord Genuity Group lowered their price objective on shares of Evolent Health from $23.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. BTIG Research lowered their price objective on shares of Evolent Health from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, December 3rd. Truist Financial lowered their price objective on shares of Evolent Health from $20.00 to $15.00 and set a “buy” rating for the company in a research report on Wednesday, January 22nd. JPMorgan Chase & Co. lowered their price objective on shares of Evolent Health from $15.00 to $13.00 and set an “overweight” rating for the company in a research report on Tuesday, January 28th. Finally, Royal Bank of Canada lowered their price objective on shares of Evolent Health from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Evolent Health presently has an average rating of “Buy” and an average price target of $17.92.

Evolent Health Trading Up 1.0 %

Shares of Evolent Health stock opened at $10.07 on Friday. The stock has a market capitalization of $1.17 billion, a P/E ratio of -11.06 and a beta of 1.45. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. The company has a 50-day simple moving average of $10.86 and a 200 day simple moving average of $19.28. Evolent Health has a 12-month low of $9.45 and a 12-month high of $35.00.

Institutional Investors Weigh In On Evolent Health

Several institutional investors have recently modified their holdings of EVH. Wellington Management Group LLP grew its position in shares of Evolent Health by 12.8% during the 3rd quarter. Wellington Management Group LLP now owns 12,595,459 shares of the technology company’s stock worth $356,200,000 after buying an additional 1,426,747 shares during the period. Point72 Asset Management L.P. boosted its stake in Evolent Health by 1,948.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,495,385 shares of the technology company’s stock worth $42,289,000 after acquiring an additional 1,422,385 shares during the last quarter. Engaged Capital LLC boosted its stake in Evolent Health by 35.5% during the 4th quarter. Engaged Capital LLC now owns 5,404,768 shares of the technology company’s stock worth $60,804,000 after acquiring an additional 1,415,300 shares during the last quarter. Boston Partners boosted its stake in Evolent Health by 92.0% during the 4th quarter. Boston Partners now owns 2,444,006 shares of the technology company’s stock worth $27,097,000 after acquiring an additional 1,171,304 shares during the last quarter. Finally, Norges Bank bought a new position in Evolent Health during the 4th quarter worth approximately $12,519,000.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.